News &amp; events

Constructive Bio's 2025 Milestones in Non-Canonical Amino Acid (ncAA) Biomanufacturing

Jan 2026

The Observer Features Constructive Bio's Sustainable Fermentation Alternative to Peptide Manufacturing Waste

Jan 2026

SynBioBeta Interviews Professor Jason Chin on Constructive Bio's Expanded Genetic Code and Novel Polymer Applications

Nov 2025

11 Oct 2025Read at Nature Biotechnology →

Constructive Bio Partners with RxCelerate to Advance ncAA-Containing Biologics Through Drug Design and Development

Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities, targeting next-generation biologics for challenging diseases.

19 Nov 2025Read →

Nature Biotechnology

publication

Constructive Bio Selected as Nature Biotechnology 2025 Editor's Pick for Synthetic Genomics and ncAA Platform

Nature Biotechnology selected Constructive Bio as a 2025 Editor's Pick, highlighting the company's work in synthetic E. coli genomes and non-canonical amino acid incorporation for next-generation biomanufacturing. The feature recognises Constructive Bio's translation of foundational genome engineering research into commercial peptide and protein production.

Constructive Bio Collaborates with Ellison Institute's Generative Biology Institute

Constructive Bio entered a collaboration with the Ellison Institute of Technology's Generative Biology Institute (GBI) in Oxford, combining synthetic genome platforms to advance new medicines, disease-resistant cells, and sustainable materials.

10 Oct 2025Read →

Cambridge iGEM 2025 Team Visits Constructive Bio's Recodery for Synthetic Biology Discussion

Constructive Bio hosted the Cambridge iGEM 2025 team at The Recodery for a technical discussion on synthetic biology research, as part of ongoing engagement with emerging researchers in genome engineering.

23 Sept 2025Read →

Constructive Bio Wins Life Science Scale-Up Award at the Business Weekly Awards, Cambridge

Constructive Bio won the Life Science Scale-Up Award at the 35th Anniversary Business Weekly Awards in Cambridge, recognising the company's growth in synthetic genomics and biomanufacturing.

15 Sept 2025Read →

Constructive Bio Joins ARIA-Funded Collaboration to Build Synthetic Chloroplast Genomes Using Large-Scale DNA Assembly

Constructive Bio is contributing its large-scale genome assembly platform to an ARIA-funded collaboration with Camena Bioscience and the Max-Planck Institute to develop synthetic chloroplast genomes for multiple plant species.

14 Aug 2025Read →

Syn57: MRC LMB Team Led by Constructive Bio's Jason Chin Creates E. coli with 57-Codon Synthetic Genome

The New York Times

1 Aug 2025Read at The New York Times →

Syn57: MRC LMB Team Led by Constructive Bio's Jason Chin Creates E. coli with 57-Codon Synthetic Genome

The New York Times reported on the creation of Syn57, an E. coli strain engineered to function with just 57 codons instead of the standard 64. The research, led by Professor Jason Chin's team at the MRC Laboratory of Molecular Biology, involved over 100,000 changes to the genome and builds on the Syn61 work that underpins Constructive Bio's platform.

event

Constructive Bio Sponsors 2025 LMB–Institut Pasteur Symposium on Molecular Biology Research

Constructive Bio sponsored the 2025 LMB–Institut Pasteur Symposium at the MRC Laboratory of Molecular Biology in Cambridge, bringing together international researchers in molecular biology and synthetic genomics.

10 Jun 2025Read →

press

Constructive Bio Licences tRNA Display Technology for Incorporating Non-Canonical Amino Acids into Peptides and Proteins

Constructive Bio has secured an exclusive licence for tRNA display technology, enabling directed integration of non-canonical amino acids (ncAAs) and other new-to-nature building blocks into peptides and proteins.

4 Jun 2025Read →

Constructive Bio Highly Commended for Biotech Company of the Year at Cambridge Independent Science Awards

Constructive Bio was Highly Commended in the Biotech Company of the Year category at the Cambridge Independent Science and Technology Awards, recognising the company's synthetic genomics platform.

15 May 2025Read →

Professor Jason Chin Receives SynBioBeta 2025 Impact Award for Contributions to Synthetic Biology and Genetic Code Engineering

Constructive Bio founder and CSO Professor Jason Chin received the SynBioBeta 2025 Impact Award, recognising his contributions to synthetic biology including creation of synthetic genomes and genetic code expansion.

5 May 2025Read →

The Sunday Times

7 Apr 2025Read at The Sunday Times →

Constructive Bio Named 'Biotech One to Watch' in The Sunday Times 100 Tech Awards 2025

The Sunday Times recognised Constructive Bio as a 'Biotech One to Watch' in its annual 100 Tech Awards for 2025. The award was accepted by CEO Ola Wlodek and CSO and founder Professor Jason Chin on behalf of the Constructive Bio team.

Constructive Bio Wins One Nucleus Award for Best Performing R&D Platform Development in Synthetic Genomics

Constructive Bio was named Best Performing R&D Platform Development Company of the Year at the One Nucleus Awards, recognising the company's synthetic genomics and engineered translation platform for biomanufacturing.

27 Mar 2025Read →

event

Constructive Bio CEO Ola Wlodek Presents on Genetic Code Expansion at Milner Therapeutics Institute

Constructive Bio CEO Ola Wlodek presented at the Milner Therapeutics Institute seminar series on rewriting genetic codes to expand the protein universe using non-canonical amino acids and synthetic genomics.

18 Mar 2025Read →

press

Constructive Bio Raises $58M Series A to Scale Fermentation-Based Peptide Manufacturing with Non-Canonical Amino Acids

Constructive Bio secured $58 million in Series A financing, bringing total funding to $75 million, to scale its BioForge fermentation platform for manufacturing peptide therapeutics with non-canonical amino acids (ncAAs).

24 Sept 2024Read →

Professor Jason Chin Reappointed to UK Department for Science, Innovation and Technology Board

UK Government (DSIT)

26 Apr 2024Read at UK Government (DSIT) →

Professor Jason Chin Reappointed to UK Department for Science, Innovation and Technology Board

The UK Government's Department for Science, Innovation and Technology (DSIT) announced the reappointment of Professor Jason Chin to its departmental board as a Non-Executive Director. Professor Chin is the founder and Chief Scientific Officer of Constructive Bio.

Constructive Bio Expands to New Cambridge Headquarters at The Recodery in the Cambridge Biomedical Cluster

Constructive Bio expanded to new headquarters in the Cambridge Biomedical Cluster, taking all lab space at Gen Two in Whittlesford to scale its synthetic genomics and biomanufacturing operations.

15 Nov 2023Read →

Financial Times Profiles Constructive Bio's Synthetic Genomics and Genetic Code Engineering

The Financial Times profiled Constructive Bio's work in synthetic genomics and genetic code rewriting, covering the Cambridge company's approach to engineering organisms with expanded biological capabilities.

14 Aug 2022Read →

Featured event

Bioprocessing Summit Europe 2026

10 March 2026 · Barcelona, Spain

Bioprocessing Summit Europe brings together 550+ professionals from industry and academia, along with 60+ exhibitors, to advance the manufacture, quality, and control of cutting-edge biologics, genetic therapies, peptides, and oligonucleotides. This year introduced a new dedicated track on Peptide and Oligo Manufacturing, focusing on the vast potential for “-tides” and routes to scaling their manufacturing.

Read our recap →

Upcoming events

TIDES USA 2026

May 2026

Boston, MA, USA

International Conference on Synthetic Biology & Bioengineering (ICSBB 2026)

May 2026

Berlin, Germany